
Human Myosin-9 1843-1851, KLKDVLLQV
Description
About Human Myosin-9 1843-1851, KLKDVLLQV
The Human Myosin 9 Peptide (IEDB: 31931) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Myosin Peptide, H-KLKDVLLQV-OH (Uniprot: P35579 aa: 1843-1851) from JPT is produced under strict quality control and quality management.
Human Myosin-9 1843-1851, KLKDVLLQV - Specifications
- Peptide sequence: H-KLKDVLLQV-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Prediabetes
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Myosin-9 1843-1851, KLKDVLLQV
References:
Read References with JPT’s Antigen Peptides
Human Myosin-9 1843-1851, KLKDVLLQV has been described in:
Incidental CD8 T cell reactivity against caspase-cleaved apoptotic self-antigens from ubiquitously expressed proteins in islets from prediabetic human leucocyte antigen-A2 transgenic non-obese diabetic mice., Clin Exp Immunol, 2011 (PMID: 21605113)
CD8+ T Cells Specific to Apoptosis-Associated Antigens Predict the Response to Tumor Necrosis Factor Inhibitor Therapy in Rheumatoid Arthritis., PLoS One, 2015 (PMID: 26061065)
HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes., J Immunol, 2006 (PMID: 16493087)
Documentation
Documentation for Human Myosin-9 1843-1851, KLKDVLLQV
Properties
Properties of Human Myosin-9 1843-1851, KLKDVLLQV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Prediabetes |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Myosin |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Myosin-9 1843-1851, KLKDVLLQV
Information | Values |
---|---|
Sequence: | H-KLKDVLLQV-OH |
Specifications: | 9mer peptide as TFA salt |